Quartz crystal microbalance (QCM), based on piezoelectric phenomena, has become an important biosensing system. This system uses a label-free and real-time biorecognition mechanism that enables the detection of a wide range of biomolecules such as proteins, nucleic acids, peptides, oligonucleotides and hormones. The application of the QCM device in DNA-based biosensors is particularly attractive because it enables real-time measurement of DNA binding and hybridization at the subnanogram level. The basic principle of this piezoelectric biosensor is that during DNA hybridization, the mass on the QCM electrode increases, which leads to a corresponding decrease in the emitted frequency. This highly sensitive system has great clinical application potential, particularly in the area of cancer assessment. It extends from treatment selection to ongoing monitoring of the patient.

In our research area, we have successfully used this innovative system for the detection of miRNA as a biomarker for liver cancer. This approach opens up promising perspectives for precise diagnoses and treatment decisions in the field of liver cancer detection. By using the QCM system, we can track developments at the genetic level in real time, which is crucial for individualized treatment and patient management.